Eric E Smith, Ashkan Shoamanesh, Lizhen Xu, Laura Heenan, Feryal Saad, Pablo Colorado, Chih-Hao Chen, Robin Lemmens, Gian Marco De Marchis, Valeria Caso, Jaime Masjuan, Teruyuki Hirano, Ivan Milanov, Bruce C V Campbell, Jean-Louis Mas, Stuart J Connolly, Hardi Mundl, Robert G Hart
BACKGROUND: Exploratory analysis of the phase 2 PACIFIC-Stroke (Program of Anticoagulation via Inhibition of FXIa by the Oral Compound BAY 2433334-Non-Cardioembolic Stroke) randomized trial suggested that asundexian, an oral factor XIa inhibitor, prevents recurrent stroke and transient ischemic attacks in patients with atherosclerotic stroke. In this post hoc exploratory analysis, we hypothesized that asundexian would be more effective in patients enrolled with large, multiple, or cortical acute infarcts on magnetic resonance imaging than in patients enrolled with a single small subcortical acute infarct, and asundexian would prevent incident cortical covert infarcts...
February 2024: Stroke; a Journal of Cerebral Circulation